| Attribute |
Value |
| 52 Week Change |
-0.19637299 |
| Address1 |
An der Goldgrube 12 |
| All Time High |
464.0 |
| All Time Low |
12.525 |
| Ask |
113.95 |
| Ask Size |
2 |
| Audit Risk |
1 |
| Average Analyst Rating |
1.5 - Buy |
| Average Daily Volume10 Day |
782,720 |
| Average Daily Volume3 Month |
959,008 |
| Average Volume |
959,008 |
| Average Volume10Days |
782,720 |
| Beta |
1.324 |
| Bid |
64.49 |
| Bid Size |
2 |
| Board Risk |
4 |
| Book Value |
84.4298 |
| City |
Mainz |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
7 |
| Country |
Germany |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
90.4 |
| Current Ratio |
8.8 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
91.2 |
| Day Low |
88.5 |
| Debt To Equity |
1.619 |
| Dividend Date |
1,655,424,000 |
| Earnings Call Timestamp End |
1,777,982,400 |
| Earnings Call Timestamp Start |
1,777,982,400 |
| Earnings Timestamp |
1,785,846,600 |
| Earnings Timestamp End |
1,785,846,600 |
| Earnings Timestamp Start |
1,785,846,600 |
| Ebitda |
-1,191,299,968 |
| Ebitda Margins |
-0.42468 |
| Enterprise To Ebitda |
-7.938 |
| Enterprise To Revenue |
3.371 |
| Enterprise Value |
9,456,936,960 |
| Eps Current Year |
-4.60427 |
| Eps Forward |
-5.037447 |
| Eps Trailing Twelve Months |
-5.78 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,654,128,000 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
49 6131 9084 |
| Fifty Day Average |
91.7316 |
| Fifty Day Average Change |
-1.3315964 |
| Fifty Day Average Change Percent |
-0.014516223 |
| Fifty Two Week Change Percent |
-19.637299 |
| Fifty Two Week High |
124.0 |
| Fifty Two Week High Change |
-33.6 |
| Fifty Two Week High Change Percent |
-0.27096772 |
| Fifty Two Week Low |
79.52 |
| Fifty Two Week Low Change |
10.880005 |
| Fifty Two Week Low Change Percent |
0.13682099 |
| Fifty Two Week Range |
79.52 - 124.0 |
| Financial Currency |
EUR |
| First Trade Date Milliseconds |
1,570,714,200,000 |
| Float Shares |
110,098,221 |
| Forward Eps |
-5.037447 |
| Forward P E |
-17.945599 |
| Free Cashflow |
-428,112,512 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
7,807 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,782,864,000 |
| Gross Margins |
0.78650004 |
| Gross Profits |
2,206,299,904 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.57129 |
| Held Percent Institutions |
0.20476 |
| Implied Shares Outstanding |
252,884,261 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Dividend Date |
1,654,128,000 |
| Last Dividend Value |
2.111 |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany. |
| Long Name |
BioNTech SE |
| Market |
us_market |
| Market Cap |
22,860,736,512 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_51198843 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-1,252,199,936 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
22,860,737,194 |
| Number Of Analyst Opinions |
20 |
| Open |
90.09 |
| Operating Cashflow |
815,699,968 |
| Operating Margins |
-5.7663 |
| Overall Risk |
5 |
| Payout Ratio |
0.0 |
| Peg Ratio |
0.05 |
| Phone |
49 6131 9084 |
| Pre Market Change |
-0.26000214 |
| Pre Market Change Percent |
-0.28761297 |
| Pre Market Price |
90.14 |
| Pre Market Time |
1,784,113,875 |
| Previous Close |
90.07 |
| Price Eps Current Year |
-19.63395 |
| Price Hint |
2 |
| Price To Book |
1.070712 |
| Price To Sales Trailing12 Months |
8.149414 |
| Profit Margins |
-0.44639 |
| Quick Ratio |
8.113 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
1.55 |
| Region |
US |
| Regular Market Change |
0.33000183 |
| Regular Market Change Percent |
0.36638373 |
| Regular Market Day High |
91.2 |
| Regular Market Day Low |
88.5 |
| Regular Market Day Range |
88.5 - 91.2 |
| Regular Market Open |
90.09 |
| Regular Market Previous Close |
90.07 |
| Regular Market Price |
90.4 |
| Regular Market Time |
1,784,059,201 |
| Regular Market Volume |
923,470 |
| Return On Assets |
-0.04178 |
| Return On Equity |
-0.06656 |
| Revenue Growth |
-0.354 |
| Revenue Per Share |
11.453 |
| Sand P52 Week Change |
0.2043345 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
1 |
| Shares Outstanding |
252,884,261 |
| Shares Percent Shares Out |
0.0092 |
| Shares Short |
2,324,296 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
2,255,806 |
| Short Name |
BioNTech SE |
| Short Percent Of Float |
0.034 |
| Short Ratio |
2.24 |
| Source Interval |
15 |
| Symbol |
BNTX |
| Target High Price |
154.44685 |
| Target Low Price |
75.895645 |
| Target Mean Price |
121.92271 |
| Target Median Price |
128.04886 |
| Total Cash |
13,706,600,448 |
| Total Cash Per Share |
54.201 |
| Total Debt |
302,800,000 |
| Total Revenue |
2,805,199,872 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-5.78 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
98.9101 |
| Two Hundred Day Average Change |
-8.510101 |
| Two Hundred Day Average Change Percent |
-0.086038746 |
| Type Disp |
Equity |
| Volume |
923,470 |
| Website |
https://www.biontech.de |
| Zip |
55,131 |